PTLF (Petlife Pharmaceuticals) Debt-to-EBITDA : -0.52 (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Petlife Pharmaceuticals Debt-to-EBITDA?

Petlife Pharmaceuticals PTLF Debt-to-EBITDA is -0.52 as of Feb. 2018.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Petlife Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2018 was $0.80 Mil. Petlife Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2018 was $0.00 Mil. Petlife Pharmaceuticals's annualized EBITDA for the quarter that ended in Feb. 2018 was $-1.53 Mil. Petlife Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2018 was -0.52.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Petlife Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

PTLF's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.62
* Ranked among companies with meaningful Debt-to-EBITDA only.

Petlife Pharmaceuticals  (OTCPK:PTLF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Petlife Pharmaceuticals Debt-to-EBITDA Related Terms

Petlife Pharmaceuticals Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Debt-to-EBITDA Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.04 -0.03

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.26 -0.11 -0.49 -0.52

PTLF vs PCYN, YBAO, BKIT: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petlife Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Petlife Pharmaceuticals's Debt-to-EBITDA falls into.


Petlife Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Petlife Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Aug. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.717 + 0) / -22.873
=-0.03

Petlife Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.802 + 0) / -1.532
=-0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2018) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.52 mean?
Petlife Pharmaceuticals (PTLF) has a Debt-to-EBITDA of -0.52 as of Feb. 2018. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Petlife Pharmaceuticals.
Is Petlife Pharmaceuticals' Debt-to-EBITDA too high?
Petlife Pharmaceuticals' current Debt-to-EBITDA is -0.52.
How does Petlife Pharmaceuticals' Debt-to-EBITDA compare to PCYN and YBAO?
Petlife Pharmaceuticals' Debt-to-EBITDA of -0.52 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Petlife Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current Debt-to-EBITDA is -0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Debt-to-EBITDA of -0.52. The current Debt-to-EBITDA is -0.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Debt-to-EBITDA is -0.52 as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.